MSB 3.21% $1.13 mesoblast limited

Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval, page-233

  1. 6,474 Posts.
    lightbulb Created with Sketch. 2630
    "there isn't quite enough merit in MSBs potency validation to give Mesblast a BLA in my opinion - that opinion of mine being based on the science and the data that is in the public domain - I think that public domain stuff is enough to make that call with a fairly high degree of confidence IF a person has enough science to understand what MSB has said and IF they are across the other material about MSB that is in the public domain. "

    This is an incredibly foolish statement. If you require an explanation why, then my statement descriptor can also be attributed to the author.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.